Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial ...News

Russia Today - News
Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial
An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second. In a press statement on Monday, Italian biotech company ReiThera said its candidate vaccine was well tolerated and “induces clear immune responses in trial subjects.”  The vaccine, called GRAd-COV2, generated an antibody response against the virus’s spike protein in over 93% of volunteers after the first dose, reaching 99% after the second. The study involved 917 volunteers over the age of 18 at 24 centers acro

Hence then, the article about italian covid 19 vaccine demonstrates safety and efficacy in phase 2 trial was published today ( ) and is available on Russia Today ( News ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News